Functional audit of the use of megaprosthesis for limb reconstruction in musculoskeletal tumors - A retrospective single-center study
- PMID: 38152425
- PMCID: PMC10749826
- DOI: 10.1016/j.jor.2023.11.069
Functional audit of the use of megaprosthesis for limb reconstruction in musculoskeletal tumors - A retrospective single-center study
Abstract
Introduction: Medical advancements in musculoskeletal oncology has significantly reduced the mortality rate associated with limb-sparing surgery, making it comparable to amputation. The use of modular megaprosthesis for sarcoma treatment has now become a standard practice. However, these non-biological implants are not without their complications.
Materials and methods: A retrospective cohort study was conducted on all patients who underwent wide resection of locally aggressive and malignant bone tumors, followed by reconstruction with megaprosthesis between January 2018 and January 2023 at tertiary care hospital. Patients were evaluated based on oncological outcomes, functional outcomes, and complications with a minimum follow-up period of 6 months.
Results: The study included a total of 30 patients, comprising 16 males and 14 females, with a mean age of 33.6 ± 15.6 years. They all underwent wide resection and reconstruction with megaprosthesis. Diagnosis among the patients included 19 cases of giant cell tumors, 5 cases of osteosarcomas, 2 cases of metastatic bone tumors, and 1 case each of chondrosarcoma, malignant fibrous histiocytoma, multiple myeloma, and chondromyxoid fibroma. These tumors were predominantly located in the distal femur (15 patients) and proximal tibia (12 patients). The average follow-up period was 33 ± 21 months, resulting in an average final Musculoskeletal Tumor Society (MSTS) score of 81 % ± 9 %. Complications were observed in 21 patients, with infection being the most common, specifically Type 4 (10 patients, 37 %), followed by Type 1 (4 patients, 13 %) and Type 3 (4 patients, 13 %). Two patients (7 %) experienced Type 5 complications, while three succumbed to their illnesses. Additionally, two patients required amputation, one due to local recurrence and the other due to a deep-seated infection.
Conclusion: Megaprosthesis is a viable reconstruction option following wide resection of bone tumors. Infection remains the most common issue, and cost poses a significant challenge.
Keywords: Benign aggressive bone tumor; Limb salvage surgery; Malignant bone tumor; Megaprosthesis.
© 2023 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures



Similar articles
-
Outcomes of a Modular Intercalary Endoprosthesis as Treatment for Segmental Defects of the Femur, Tibia, and Humerus.Clin Orthop Relat Res. 2016 Feb;474(2):539-48. doi: 10.1007/s11999-015-4588-z. Clin Orthop Relat Res. 2016. PMID: 26475032 Free PMC article.
-
Are Complications Associated With the Repiphysis(®) Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use?Clin Orthop Relat Res. 2015 Sep;473(9):3003-13. doi: 10.1007/s11999-015-4355-1. Epub 2015 May 21. Clin Orthop Relat Res. 2015. PMID: 25995179 Free PMC article.
-
[Non-cemented modular prosthetic reconstruction for bone defect after tumor resection in lower extremities].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2019 Sep 15;33(9):1108-1115. doi: 10.7507/1002-1892.201904057. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2019. PMID: 31512451 Free PMC article. Clinical Trial. Chinese.
-
Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.BMC Musculoskelet Disord. 2022 Sep 30;23(1):890. doi: 10.1186/s12891-022-05840-6. BMC Musculoskelet Disord. 2022. PMID: 36180843 Free PMC article. Review.
-
Non-neoplastic indications and outcomes of the proximal and distal femur megaprosthesis: a critical review.Knee Surg Relat Res. 2020 Apr 9;32(1):18. doi: 10.1186/s43019-020-00034-7. Knee Surg Relat Res. 2020. PMID: 32660578 Free PMC article. Review.
Cited by
-
Effect of Plate Configuration in the Primary Stability of Osteotomies and Biological Reconstructions of Femoral Defects: Finite-Element Study.Bioengineering (Basel). 2024 Apr 24;11(5):416. doi: 10.3390/bioengineering11050416. Bioengineering (Basel). 2024. PMID: 38790284 Free PMC article.
-
A biosynthetic thumb prosthesis.NPJ Biomed Innov. 2025;2(1):22. doi: 10.1038/s44385-025-00031-z. Epub 2025 Jul 2. NPJ Biomed Innov. 2025. PMID: 40620413 Free PMC article.
References
-
- Özger H., Alpan B., Salduz A., et al. Mid-term implant survival, functional and radiological results and mechanical complications of mega-prosthetic reconstruction around the knee with the PENTA® system. Arch Orthop Trauma Surg. 2022 Sep;142(9):2323–2333. doi: 10.1007/s00402-021-04108-3. Epub 2021 Aug 21. PMID: 34417851; PMCID: PMC9381614. - DOI - PMC - PubMed
-
- Bacci G., Ferrari S., Bertoni F., et al. Longterm outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–4027. - PubMed
-
- Bacci G., Ferrari S., Comandone A., Zanone A., Ruggieri P., Longhi A., Bertoni F., Forni C., Versari M., Rimondini S. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000;39:111–116. - PubMed
-
- Bacci G., Picci P., Ferrari S., et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma for the extremities: the recent experience at the Rizzoli Institute. Cancer Treat Res. 1993;62:299–308. - PubMed
-
- Bacci G., Picci P., Ferrari S., et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227–3238. - PubMed
LinkOut - more resources
Full Text Sources